SCHEMBL1049892

SCHEMBL1049892

C/C(=N\O)C(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 11/20 0.60
CES1 P23141 10/20 0.60
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.47
CYP2C19 P33261 1/20 0.47
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
GLA P06280 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 1/20 0.45
XBP1 P17861 1/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
DAO P14920 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108031 1.00 CES2 (0.60) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL449946 1.00 CES2 (0.60) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL28138711 1.00 CES2 (0.60) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11488533 0.88 SMN1; SMN2 (0.59) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11373661 0.88 SMN1; SMN2 (0.59) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11373666 0.88 SMN1; SMN2 (0.59) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11424490 0.85 CES2 (0.54) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11714645 0.83 PARP10 (0.53) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL11714663 0.83 PARP10 (0.53) CES2CES1MAPTSMN1; SMN2POLB
SCHEMBL28543716 0.82 CES2 (0.50) CES2CES1MAPTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114133467-B Unsaturated esterified monomer and ester low-bleeding polycarboxylate superplasticizer and preparation method thereof 科之杰新材料集团浙江有限公司 2023-04-18 CN claimed
CN-114133467-A Unsaturated esterified monomer and ester low-bleeding polycarboxylate superplasticizer and preparation method thereof 科之杰新材料集团浙江有限公司 2022-03-04 CN claimed
CN-109485806-B Ester type super-slow-release polycarboxylic slump retaining agent and preparation method thereof 科之杰新材料集团(广东)有限公司 2021-02-26 CN claimed
CN-109485806-A A kind of super sustained-release polycarboxylic slump retaining agent of esters and preparation method thereof 广东科之杰新材料有限公司 2019-03-19 CN claimed
US-20050020672-A1 Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals THE PROCTER & GAMBLE COMPANY 2005-01-27 US claimed
EP-0754039-A4 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS PROCTER & GAMBLE (US) 2002-07-17 EP claimed
EP-1206241-A1 METHODS OF LIGHTENING KERATINOUS TISSUE BY TOPICAL APPLICATION OF OXIME COMPOUND CONTAINING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2002-05-22 EP claimed
US-6287373-B1 FOR ACOUSTIC INK JET PRINTING XEROX CORPORATION 2001-09-11 US claimed
WO-2001013882-A1 METHODS OF LIGHTENING KERATINOUS TISSUE BY TOPICAL APPLICATION OF OXIME COMPOUND CONTAINING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2001-03-01 WO claimed
US-6187082-B1 COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT XEROX CORPORATION 2001-02-13 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
CN-1145782-A Method of using iron chelating compounds to reduce free radical damage in mammals PROCTER & GAMBLE (US) 1997-03-26 CN claimed
EP-0754039-A1 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS THE PROCTER & GAMBLE COMPANY (US) 1997-01-22 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
WO-1995027485-A1 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS THE PROCTER & GAMBLE COMPANY (US) 1995-10-19 WO claimed
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
EP-4583933-A1 FLUOROPOLYMER MEDICAL DEVICES Unomedical A/S (DK) 2025-07-16 EP disclosed
EP-4583934-A1 MEDICAL DEVICES Unomedical A/S (DK) 2025-07-16 EP disclosed
WO-2024168218-A1 WEARABLE ELECTROPHYSIOLOGICAL MONITORING SYSTEMS THE UNIVERSITY OF MASSACHUSETTS (US) 2024-08-15 WO disclosed
EP-4376912-A1 INTERMITTENT CATHETERS ConvaTec Limited (GB) 2024-06-05 EP disclosed
EP-4376909-A1 INTERMITTENT CATHETERS ConvaTec Limited (GB) 2024-06-05 EP disclosed
EP-4346935-A1 COATING FOR MEDICAL DEVICES Smart Reactors Service Limited (IE) 2024-04-10 EP disclosed
WO-2024058031-A1 ACTINIC-RAY-CURABLE RESIN COMPOSITION, CURED OBJECT, AND MULTILAYERED OBJECT 荒川化学工業株式会社 2024-03-21 WO disclosed
WO-2024052192-A1 FLUOROPOLYMER MEDICAL DEVICES UNOMEDICAL A/S (DK) 2024-03-14 WO disclosed
WO-2024052193-A1 MEDICAL DEVICES UNOMEDICAL A/S (DK) 2024-03-14 WO disclosed
WO-2023234365-A1 SOFT CONTACT LENS HAVING COATING LAYER 日油株式会社 2023-12-07 WO disclosed
EP-4259822-A1 SINGLE-BUFFER COMPOSITIONS FOR NUCLEIC ACID DETECTION Mammoth Biosciences, Inc. (US) 2023-10-18 EP disclosed
CN-116830039-A Photosensitive resin composition, photosensitive resin sheet, cured product, hollow structure, electronic component, and elastic wave filter 东丽株式会社 2023-09-29 CN disclosed
CN-116710391-A Hollow structure, and electronic component and negative photosensitive resin composition using same 东丽株式会社 2023-09-05 CN disclosed
CN-114730127-B Photosensitive resin composition, photosensitive resin sheet, hollow structure, cured product, method for producing hollow structure, electronic component, and elastic wave filter 东丽株式会社 2023-05-12 CN disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed
CN-114133467-B Unsaturated esterified monomer and ester low-bleeding polycarboxylate superplasticizer and preparation method thereof 科之杰新材料集团浙江有限公司 2023-04-18 CN disclosed
EP-4130154-A1 CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT Asahi Kasei Kabushiki Kaisha (JP) 2023-02-08 EP disclosed
WO-2023007131-A1 INTERMITTENT CATHETERS CONVATEC LIMITED (GB) 2023-02-02 WO disclosed
WO-2023007128-A1 INTERMITTENT CATHETERS CONVATEC LIMITED (GB) 2023-02-02 WO disclosed
WO-2022271873-A2 PROGRAMMABLE NUCLEASE DIAGNOSTIC DEVICE MAMMOTH BIOSCIENCES, INC. (US) 2022-12-29 WO disclosed
WO-2022253780-A1 COATING FOR MEDICAL DEVICES Smart Reactors Service Limited (IE) 2022-12-08 WO disclosed
WO-2022241032-A1 ENHANCED GUIDE NUCLEIC ACIDS AND METHODS OF USE MAMMOTH BIOSCIENCES, INC. (US) 2022-11-17 WO disclosed
CN-115190901-A Carbodiimide composition, curing agent composition, coating composition, and resin cured product 旭化成株式会社 2022-10-14 CN disclosed
WO-2022132833-A1 SINGLE-BUFFER COMPOSITIONS FOR NUCLEIC ACID DETECTION MAMMOTH BIOSCIENCES, INC. (US) 2022-06-23 WO disclosed
CN-114133467-A Unsaturated esterified monomer and ester low-bleeding polycarboxylate superplasticizer and preparation method thereof 科之杰新材料集团浙江有限公司 2022-03-04 CN disclosed
CN-109485806-B Ester type super-slow-release polycarboxylic slump retaining agent and preparation method thereof 科之杰新材料集团(广东)有限公司 2021-02-26 CN disclosed
WO-2020129087-A1 NOVEL PROCESS FOR THE PREPARATION OF R-PHENYLACETYLCARBINOL AND β-AMINOALCOHOLS MALLADI DRUGS AND PHARMACEUTICALS LTD. (IN) 2020-06-25 WO disclosed
CN-109485806-A A kind of super sustained-release polycarboxylic slump retaining agent of esters and preparation method thereof 广东科之杰新材料有限公司 2019-03-19 CN disclosed
CN-105951307-A High-performance anti-radiation metal fabric and preparation method thereof 苏州洪河金属制品有限公司 2016-09-21 CN disclosed
EP-2753604-B1 PDE10 MODULATORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US disclosed
WO-2013034506-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-14 WO disclosed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US disclosed
EP-1599454-B1 DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2012-12-26 EP disclosed
US-8318796-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-11-27 US disclosed
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2011-03-31 US disclosed
US-20110064662-A1 KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY RIKEN (JP) 2011-03-17 US disclosed
US-7872034-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-18 US disclosed
US-7872034-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-18 US disclosed
US-7872034-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-18 US disclosed
EP-2228363-A1 KIT FOR USE IN PRODUCTION OF MOLECULAR PROBE FOR PET DRUG SCREENING Riken (JP) 2010-09-15 EP disclosed
US-7615321-B2 Color filter DAI NIPPON PRINTING CO., LTD. (JP) 2009-11-10 US disclosed
EP-1756096-B1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-08-12 EP disclosed
EP-1599455-B1 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
EP-1599455-B1 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
EP-1735266-B1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-ERYTHRO-2-AMINO-1-PHENYL-1-PROPANOL EMMELLEN BIOTECH PHARMACEUTICA (IN) 2009-06-24 EP disclosed
EP-1599453-B1 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-05-06 EP disclosed
EP-1599453-B1 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-05-06 EP disclosed
US-7485652-B2 Indolyl derivatives as liver-X-receptor (LXR) modulators HOFFMANN-LA ROCHE INC. (US) 2009-02-03 US disclosed
US-7470713-B2 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 US disclosed
US-7470713-B2 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 US disclosed
US-7470713-B2 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 US disclosed
CN-100439345-C (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexylmethoxy acetic acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis. SANNOFFE AVENTIS PHARMA GMBH (DE) 2008-12-03 CN disclosed
US-20080286666-A1 COLOR FILTER AND METHOD OF PRODUCING SAME KOBAYASHI HIRONORI 2008-11-20 US disclosed
US-7414153-B2 Process for preparation of optically active 1-erythro-2-amino-1-phenyl-1-propanol EMMELLEN BIOTECH PHARMACEUTICALS LIMITED (IN) 2008-08-19 US disclosed
US-7414153-B2 Process for preparation of optically active 1-erythro-2-amino-1-phenyl-1-propanol EMMELLEN BIOTECH PHARMACEUTICALS LIMITED (IN) 2008-08-19 US disclosed
US-20080167354-A1 ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-10 US disclosed
US-20080167354-A1 ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-10 US disclosed
US-20080167354-A1 ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-10 US disclosed
CN-100398526-C 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis SANOFI AVENTIS DEUTSCHLAND (DE) 2008-07-02 CN disclosed
US-7365084-B2 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-29 US disclosed
US-7365084-B2 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-29 US disclosed
US-7365084-B2 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-29 US disclosed
US-7335671-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-26 US disclosed
US-7335671-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-26 US disclosed
US-7335671-B2 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-26 US disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-20070203363-A1 Process For Preparation Of Optically Active 1-Erythro-2-Amino-1-Phenyl-1-Propanol EMMELLEN BIOTECH PHARMACEUTICALS LIMITED (IN) 2007-08-30 US disclosed
US-20070203363-A1 Process For Preparation Of Optically Active 1-Erythro-2-Amino-1-Phenyl-1-Propanol EMMELLEN BIOTECH PHARMACEUTICALS LIMITED (IN) 2007-08-30 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
US-20070146914-A1 Color filter DAI NIPPON PRINTING CO., LTD. (JP) 2007-06-28 US disclosed
EP-1599452-B1 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-06-20 EP disclosed
EP-1599452-B1 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-06-20 EP disclosed
US-20070099916-A1 Indolyl derivatives as liver-x-receptor (LXR) modulators DEHMLOW HENRIETTA 2007-05-03 US disclosed
CN-1950365-A Indolyl derivatives as liver-X-receptor modulators HOFFMANN LA ROCHE (CH) 2007-04-18 CN disclosed
EP-1756096-A1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
US-7173048-B2 Indolyl derivatives as liver-X-receptor (LXR) modulators HOFFMANN-LA ROCHE INC. (US) 2007-02-06 US disclosed
US-20060222970-A1 Color filter and method of producing same DAI NIPPON PRINTING CO., LTD. 2006-10-05 US disclosed
CN-1756748-A 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis SANOFI AVENTIS DEUTSCHLAND (DE) 2006-04-05 CN disclosed
CN-1753879-A 3- (2-phenyl-oxazol-4-ylmethoxy) cyclohexyl methoxyacetic acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis SANNOFFE AVENTIS PHARMA GMBH (DE) 2006-03-29 CN disclosed
US-20060054290-A1 Novel catalytic activities of oxidoreductases for oxidation and or bleaching CALL HANS-PETER 2006-03-16 US disclosed
EP-1599453-A1 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
EP-1599454-A2 DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
EP-1599455-A1 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
EP-1599452-A1 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-30 EP disclosed
WO-2005105791-A1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-10 WO disclosed
US-20050245515-A1 Indolyl derivatives as liver-X-receptor (LXR) modulators F. HOFFMANN-LA ROCHE AG (CH) 2005-11-03 US disclosed
US-20050215596-A1 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-29 US disclosed
WO-2005082885-A1 IMIDAZOLE BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-09 WO disclosed
US-20050187218-A1 Imidazole based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-08-25 US disclosed
US-20050147766-A1 Process for manufacturing pattern forming body AOKI DAIGO (JP) 2005-07-07 US disclosed
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-05-12 US disclosed
US-20050020672-A1 Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals THE PROCTER & GAMBLE COMPANY 2005-01-27 US disclosed
US-20050020672-A1 Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals THE PROCTER & GAMBLE COMPANY 2005-01-27 US disclosed
US-20040209920-A1 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-21 US disclosed
WO-2004076427-A1 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed
WO-2004076426-A1 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed
WO-2004076428-A1 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed
WO-2004075815-A2 DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-10 WO disclosed
EP-1436371-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING Call, Krimhild (DE) 2004-07-14 EP disclosed
US-20030129321-A1 Process for manufacturing pattern forming body DAI NIPPON PRINTING CO., LTD. (JP) 2003-07-10 US disclosed
US-20030018165-A1 Uses of suppressive macrophage activation factors INNOGENETICS N.V. (BE) 2003-01-23 US disclosed
WO-2002099023-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING CALL, KRIMHILD (DE) 2002-12-12 WO disclosed
EP-1233779-A2 NEW USES OF SUPPRESSIVE MACROPHAGE ACTIVATION FACTORS INNOGENETICS N.V. (BE) 2002-08-28 EP disclosed
EP-0754039-A4 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS PROCTER & GAMBLE (US) 2002-07-17 EP disclosed
US-6328943-B1 CONTACTING IRON SULFIDES AND/OR PRECURSORS THEREOF IN THE PRESENCE OF AIR WITH AN EFFECTIVE INHIBITING AMOUNT OF A TREATMENT COMPOUND SELECTED FROM AMINE, ALCOHOL, KETONE, OR MIXTURES BETZDEARBORN INC. 2001-12-11 US disclosed
US-6287373-B1 FOR ACOUSTIC INK JET PRINTING XEROX CORPORATION 2001-09-11 US disclosed
WO-2001039786-A2 NEW USES OF SUPPRESSIVE MACROPHAGE ACTIVATION FACTORS INNOGENETICS N.V. (BE) 2001-06-07 WO disclosed
EP-0820435-B1 METHOD OF PREPARING ESSENTIALLY PURE ISOMERS OF ALPHA-BIS-OXIMES BASF AG (DE) 2001-05-16 EP disclosed
US-6187082-B1 COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT XEROX CORPORATION 2001-02-13 US disclosed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP disclosed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP disclosed
EP-1012376-A2 OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS Blume, Hildegard (DE) 2000-06-28 EP disclosed
EP-0873307-B1 CYANIMINO OXIME ETHERS, PROCESS AND INTERMEDIATES FOR THE PREPARATION AND USE THEREOF FOR THE CONTROL OF NOXIOUS FUNGI AND ANIMAL PESTS BASF AG (DE) 2000-05-31 EP disclosed
US-6063813-A FUNGICIDES AND INSECTICIDES BASF AKTIENGESELLSCHAFT (DE) 2000-05-16 US disclosed
US-6045607-A FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING XEROX CORPORATION (US) 2000-04-04 US disclosed
US-5929279-A Preparation of Bisoximes BASF AKTIENGESELLSCHAFT (DE) 1999-07-27 US disclosed
US-5922758-A REDUCING OR PREVENTING OZONE, SMOKE AND/OR POLLUTION DAMAGE TO MAMMALIAN SKIN BY APPLYING A MAMMALIAN SKIN AN EFFECTIVE AMOUNT OF COMPOUND SELECTED FROM 2,4-DIENOIC ACID ESTER OF TOCOPHEROLS, SUCH AS ALPHA, BETA, ZETA1, ZETA2 AND OTHERS THE PROCTER & GAMBLE COMPANY (US) 1999-07-13 US disclosed
WO-1998059108-A2 OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS BLUME, HILDEGARD (DE) 1998-12-30 WO disclosed
US-5739156-A ADMINISTERING TO REDUCE NONULTRAVIOLET-INDUCED FREE RADICAL DAMAGE OR AGING THE PROCTER & GAMBLE COMPANY (US) 1998-04-14 US disclosed
EP-0820435-A1 METHOD OF PREPARING ESSENTIALLY PURE ISOMERS OF $g(a)-BIS-OXIMES BASF AKTIENGESELLSCHAFT (DE) 1998-01-28 EP disclosed
CN-1145782-A Method of using iron chelating compounds to reduce free radical damage in mammals PROCTER & GAMBLE (US) 1997-03-26 CN disclosed
CN-1145782-A Method of using iron chelating compounds to reduce free radical damage in mammals PROCTER & GAMBLE (US) 1997-03-26 CN disclosed
EP-0754039-A1 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS THE PROCTER & GAMBLE COMPANY (US) 1997-01-22 EP disclosed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP disclosed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP disclosed
WO-1996032373-A1 METHOD OF PREPARING ESSENTIALLY PURE ISOMERS OF α-BIS-OXIMES BASF AKTIENGESELLSCHAFT (DE) 1996-10-17 WO disclosed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US disclosed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US disclosed
WO-1995027485-A1 METHODS OF USING IRON CHELATING COMPOUNDS TO REDUCE FREE RADICAL DAMAGE IN MAMMALS THE PROCTER & GAMBLE COMPANY (US) 1995-10-19 WO disclosed
US-5364617-A Protection from solar radiation, chelate with iron in body and reduce its ability to catalyze formation of oxygen free radicals THE PROCTER & GAMBLE COMPANY (US) 1994-11-15 US disclosed
US-4818770-A APPLYING ALPHA-DIFLUOROMETHYL-ORNITHINE INHIBITOR BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) 1989-04-04 US disclosed
WO-1988002986-A1 PREVENTION OF A PLANT DISEASE BY SPECIFIC INHIBITION OF FUNGAL POLYAMINE BIOSYNTHESIS BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) 1988-05-05 WO disclosed
EP-0129381-B1 RECORD MATERIAL The Wiggins Teape Group Limited (GB) 1987-08-12 EP disclosed
EP-0097124-B1 PROCESS FOR THE PHOTOPOLYMERISATION OF UNSATURATED COMPOUNDS CIBA-GEIGY AG (CH) 1986-10-15 EP disclosed
US-4574294-A Record material THE WIGGINS TEAPE GROUP LIMITED (GB) 1986-03-04 US disclosed
US-4567498-A CONTAINING CATIONIC SOFTENING AGENT THE WIGGINS TEAPE GROUP LIMITED (GB) 1986-01-28 US disclosed
US-4498964-A PHOTOINITIATORS FOR HIGH-SPEED CURING OF PRINTING INKS, PAINTS, PHOTORESISTS AND FILMS CIBA-GEIGY CORPORATION (US) 1985-02-12 US disclosed
EP-0129381-A1 Record material The Wiggins Teape Group Limited (GB) 1984-12-27 EP disclosed
EP-0129380-A1 Record material The Wiggins Teape Group Limited (GB) 1984-12-27 EP disclosed
EP-0097124-A2 Process for the photopolymerisation of unsaturated compounds CIBA-GEIGY AG (CH) 1983-12-28 EP disclosed
EP-0000082-B1 PROCESS FOR IMAGE-WISE MODIFYING THE SURFACE OF AN ETCHABLE SUPPORT AND MATERIAL SUITABLE THEREFOR COMPRISING A COLLOID LAYER CONTAINING POLYMERS WITH OXIME-ESTER GROUPS AGFA-GEVAERT N.V. (BE) 1982-07-21 EP disclosed
EP-0014344-B1 COUMARIN COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS WHITENERS AND LASER DYES BAYER AG (DE) 1982-04-21 EP disclosed
US-4326066-A Triazolyl coumarin compounds, processes for their preparation and their use as whiteners and laser dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1982-04-20 US disclosed
US-4293552-A Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas ELI LILLY AND COMPANY (US) 1981-10-06 US disclosed
EP-0014344-A1 Coumarin compounds, process for their preparation and their use as whiteners and laser dyes BAYER AG (DE) 1980-08-20 EP disclosed
US-4202697-A Production of etch-resist colloid and material suitable therefor AGFA-GEVAERT N.V. (BE) 1980-05-13 US disclosed
US-4160834-A INSECTICIDES ELI LILLY AND COMPANY (US) 1979-07-10 US disclosed
EP-0000082-A1 Process for image-wise modifying the surface of an etchable support and material suitable therefor comprising a colloid layer containing polymers with oxime-ester groups AGFA-GEVAERT N.V. (BE) 1978-12-20 EP disclosed
US-4083977-A Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas ELI LILLY AND COMPANY (US) 1978-04-11 US disclosed
US-4083977-A Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas ELI LILLY AND COMPANY (US) 1978-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167354-A1 ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS GPR119, FFAR1, FFAR2 CES2 404/4885CES1 109/4885MAPT 4175/4885
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 CES2 3384/4885CES1 3557/4885MAPT 3117/4885
US-20050245515-A1 Indolyl derivatives as liver-X-receptor (LXR) modulators INSR, NR1H2, NR1H3 CES2 1726/4885CES1 56/4885MAPT 3167/4885
US-20050215596-A1 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals DNPEP, DDC, AADAT CES2 325/4885CES1 1582/4885MAPT 914/4885
US-20030018165-A1 Uses of suppressive macrophage activation factors ILF3, ILF2, MIF CES2 4790/4885CES1 3879/4885MAPT 4724/4885
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS GPR119, PC, ACADM CES2 266/4885CES1 78/4885MAPT 3874/4885
US-20050020672-A1 Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals TXNRD2, PRDX5, PLPBP CES2 4233/4885CES1 3291/4885MAPT 4534/4885
US-20070203363-A1 Process For Preparation Of Optically Active 1-Erythro-2-Amino-1-Phenyl-1-Propanol HMOX1, HMOX2, OXER1 CES2 4524/4885CES1 3220/4885MAPT 2919/4885
US-20070099916-A1 Indolyl derivatives as liver-x-receptor (LXR) modulators INSR, NR1H2, NR1H3 CES2 1726/4885CES1 56/4885MAPT 3167/4885
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 CES2 538/4885CES1 1449/4885MAPT 486/4885
US-20130059833-A1 PDE10 MODULATORS PDE10A, PDE5A, PDE2A CES2 479/4885CES1 200/4885MAPT 1196/4885
US-20040209920-A1 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals GPR119, FFAR1, FFAR2 CES2 362/4885CES1 47/4885MAPT 4342/4885
US-20050187218-A1 Imidazole based kinase inhibitors MAP3K19, MAP3K1, ABL1 CES2 4498/4885CES1 3373/4885MAPT 2267/4885
US-20110064662-A1 KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY KIT, TPX2, RUNX1 CES2 465/4885CES1 2322/4885MAPT 3061/4885
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals GPR119, PC, CPT1A CES2 213/4885CES1 83/4885MAPT 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.